AI-Accelerated Big Pharma
Christian@miamidegen
· 1
+5.2%
since Oct 6
The idea
I believe big pharma companies with real, funded AI programs will discover and launch drugs faster than the market expects, while still being priced like old-school slow movers. The basket splits between the strongest AI adopters and companies facing patent cliffs that make AI-speed pipelines urgent, spread across seven names so no single company carries the thesis. I'm holding a small cash reserve and treating this as a multi-year structural bet, one I'd rethink if these companies' AI programs stall or fail to show real pipeline results.
What it owns
- These companies have built funded AI programs into their research operations and can profit while those programs mature into drugs. · Eli Lilly and CompanyIt operates a dedicated AI discovery lab built with NVIDIA and funded drug-discovery work with Insilico to produce candidates faster than its historical pipeline., Novartis AGIt is buying AI speed through discovery partnerships and a major acquisition to translate external capabilities into trials faster., AstraZeneca PLCIt has embedded AI across its entire research process rather than isolating it to one project, with trial timelines shortening against its own history., Sanofi SAIt is rebuilding the entire company around AI capabilities to shorten development times from discovery through launch., Johnson & JohnsonIt owns active AI discovery partnerships backed by a balance sheet large enough to see programs through to market, a lower-risk path to faster drug development.64%
- Patent losses force these companies to rebuild pipelines faster, so AI-accelerated discovery shows measurable results sooner. · Merck & Co.It faces exclusivity loss on a major drug and must use AI-speed development to rebuild its pipeline fast enough to offset the revenue cliff., Pfizer Inc.It has already endured a patent cliff and is rebuilding through a documented AI partnership to produce candidates instead of cutting costs.26%
- Cash10%